Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 189,600 shares, an increase of 183.8% from the March 31st total of 66,800 shares. Based on an average trading volume of 2,030,000 shares, the days-to-cover ratio is presently 0.1 days.
Biodexa Pharmaceuticals Price Performance
NASDAQ:BDRX opened at $0.72 on Friday. The stock has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $2.22. Biodexa Pharmaceuticals has a 52-week low of $0.67 and a 52-week high of $21.44.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH assumed coverage on Biodexa Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $8.00 price objective for the company.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme.
Further Reading
- Five stocks we like better than Biodexa Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- Hasbro’s Management Made All the Right Calls This Quarter
- Dividend Payout Ratio Calculator
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Election Stocks: How Elections Affect the Stock Market
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Biodexa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodexa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
